List of Duetact drug patents
Duetact is owned by Takeda Pharms Usa.
Duetact contains Glimepiride; Pioglitazone Hydrochloride.
Duetact has a total of 2 drug patents out of which 0 drug patents have expired.
Duetact was authorised for market use on 28 July, 2006.
Duetact is available in tablet;oral dosage forms.
The generics of Duetact are possible to be released after 08 June, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7700128 | TAKEDA PHARMS USA | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
Jan, 2027
(3 years from now) | |
| US8071130 | TAKEDA PHARMS USA | Solid preparation |
Jun, 2028
(5 years from now) | |
Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 July, 2006
Treatment: NA
Dosage: TABLET;ORAL
DUETACT family patents
6
Japan
3
Korea, Republic of
2
South Africa
2
Australia
2
Russia
2
Morocco
2
Norway
2
United States
2
Argentina
2
Croatia
2
Brazil
2
Spain
2
Peru
2
Taiwan, Province of China
2
China
2
Georgia
2
Canada
2
New Zealand
2
European Union
1
Israel
1
Denmark
1
Mexico
1
Jordan
1
Slovenia
1
Hungary
1
Costa Rica
1
Portugal
1
Cyprus
1
Malaysia
1
Poland
1
Ukraine
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic